Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.

Slides:

Advertisements

Similar presentations

OIE First Global Conference on Veterinary Legislation 1 Control of Veterinary Products: The Need for Global Standards Merton V. Smith, Ph.D., J.D. Director,

Advertisements

Animal Experimentation – an Introduction Made in the interest of Animals by FIAPO. Please direct any queries to Alokparna Sengupta at

1 The Protocol on Water and Health: making a difference where health, environment and development policies meet The Protocol on Water and Health.

Session 6 : Need for good governance Importance of veterinary legislation and its appropriate implementation Jean-Luc ANGOT, CVO, France 14 March 2013.

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.

Status of implementation of the Ronald Vargas and Ines Beernaerts Food and Agriculture Organization of the United Nations Samarkand, Uzbekistan - 10 September.

Steven D. Vaughn, DVM Director Office of New Animal Drug Evaluation Center for Veterinary Medicine U. S. Food and Drug Administration June 6, 2012 Embracing.

Dr. Michael E. Oehlsen International Policy Analyst International Programs Team - Office of the Director Center for Veterinary Medicine Food and Drug Administration.

Dr. Tran Thi Giang Huong Director General Department of International Cooperation.

The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January

1 Webinar on: Establishing a Fully Integrated National Food Safety System with Strengthened Inspection, Laboratory and Response Capacity Sponsored by Partnership.

ICH-GCG June 2009 Pan American Health Organization CURRENT STATUS OF PAN AMERICAN NETWORK FOR DRUG REGULATORY HARMONIZATION (PANDRH): James Fitzgerald.

Education of Veterinarians Ron Johnson, DVM, PhD, DACVCP Ontario Veterinary College Toronto, ON November 1, 2011.

Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk

Emerging infections and Health Protection In Scotland Looking to the future Kirsty Roy and Martin Donaghy Health Protection Scotland Scottish Government.

One Health Grand Challenge: Major Themes for Transformative*, Collaborative Research November 12, 2013 * High socioeconomic impact on state/national/global.

NATIONAL CAPACITY FOR EVALUATION OF EVIDENCE AND DECISION-MAKING Mauro Toledo Marrelli Universidade de São Paulo.

Libyan-UK partnership on Infectious Diseases Control Professor Abdulhafid A. Abudher MBBch,DGO,FRCOG,MD,FABOG Director of National Centre for Infectious.

Working with UICC’s 800+ member organisations in 155 countries, the McCabe Centre aims to build legal capacity globally. Based at CCV in Melbourne, Australia.

The Antimicrobial Resistance Issue A briefing for the Secretaries Advisory Committee on Animal Health June 19, 2014.

SAICM Health Sector Engagement 2 |2 | Health Sector and SAICM In 2003 countries asked WHO to facilitate participation of global health partners in SAICM.

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.

World Health Organization

An agency of the European Union Presented by: Kornelia Grein Role of VICH and VICH guidelines in marketing authorizations 2 nd VICH Outreach Forum meeting,

Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.

Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.

1 Outcome of the 4 th Global Animal Health Conference (GAHC) June 2015 Bettye K. Walters, DVM US Food and Drug Administration

JMAFF (Chair of Biologicals Quality Monitoring EWG)

VICH General Principles and current update of VICH Outreach Forum activity 1.

VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.

Health Canada’s Approach to Low Risk Veterinary Health Products: Interim Notification Pilot Program Veterinary Drugs Directorate-Health Canada Presented.

Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.

Emerging Threats Program. Why One Health in the Africa Region? Dr. Dennis Carroll Director, Emerging Threats U.S. Agency for International Development.

GLP/GCP: Requirement and implementation (Japan) Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan 1 5 th VICH Outreach.

-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.

1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.

ARIMNet Presentation ARIMNet A cooperative network for Agricultural Research in the Mediterranean Michel DODET Coordinator.

Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.

An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.

The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.

VICH Outreach Forum OIE contribution 2 nd meeting of the Forum members Washington, 19 – 20 February 2013 S. Munstermann, JP Orand, C. Lambert.

Session 5: 3Rs statement VICH5 Conference, October 2015, Tokyo 1.

Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.

How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.

The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.

VICH Task Force for Efficacy Studies for Combination Products Progress Report (Final) VICH members JMAFF (chair)K. Noda JVPAE. Oishi IFAH-EUM. Bobey EUK.

An agency of the European Union Consultation on draft VICH guidelines in the EU 2nd VICH Outreach Forum meeting, February 2013 Presented by: Kornelia.

1 THE OIE REPORT 32 nd VICH SC Meeting / 6 th VICH Outreach Forum Meeting Jean-Pierre Orand, Anses, France, OIE Collaborating Centre.

How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.

1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.

1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.

Update of Results of the Survey on training Priorities

Hervé Marion, DVM VICH Secretariat

VICH General Principles and

Requirements for GLP and GCP in the EU

EAST AFRICAN COMMUNITY MEDICINES REGULATORY HARMONIZATION (EAC-MRH) PROJECT PROGRESS NAIROB I - KENYA By: EAC - Secretariat.

The OIE report 30th VICH SC Meeting / 4th VICH Outreach Forum Meeting

Michelle Limoli, Pharm.D.

The Vision for the Future

Report by the VICH Steering Committee on issues raised by Forum members during the 1st Outreach Forum meeting Hervé Marion, DVM VICH Secretariat.

The Sixth Strategic Plan: Camels Concerned

Waiving Target Animal Batch Safety Testing for vaccines

The expectations from VICH Outreach Forum members

The Benefits of VICH to Emerging Countries

Workshop for OIE National Focal Points for Wildlife

World Health Organization

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Saudi Arabia: Veterinary Pharmaceutical Legislations &

Hervé Marion, DVM VICH Secretariat

Presentation transcript:

Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF

1. Outcome of VICH to the World 2. Phase 4 VICH Priorities ( ) 3. Vision for the Future 1. Outcome of VICH to the World 2. Phase 4 VICH Priorities ( ) 3. Vision for the Future 2

3 1. Outcome of VICH to the World

VICH has contributed to VICH regions Harmonization of technical requirements in VICH regions 4 VICH Guidelines (53 final GLs) Pharmaceuticals (40) -Quality (14) -Efficacy (10) -Environmental Safety (2) -Metabolism and Residues (4) -Toxicology (7) -Target Animal Safety (1) -Antimicrobial Safety (2) Biologicals (6) -Quality (3) -Target Animal Safety (3) General (7) -GCP (1) -Pharmacovigilance (5) -File Format (1)

VICH has contributed to the VICH regions 5 Harmonization of technical requirements in VICH regions VICH GLs are very useful for VICH regions to Ensure product quality, safety and efficacy Reduce animal testing and costs of development Accelerate the development and reviewing process Increase availability of new veterinary medicinal products Contribute to animal/public health, environment

Great Outcome of VICH for participants 6 Full Discussion to reach the best consensus in SC, Task Forces and EWGs Mutual understanding & Trust among VICH participants

VICH and OIE aim to disseminate the outcome of VICH to the World through VICH Outreach Forum. VICH GLs are useful for non-VICH countries

8 2. Phase 4 VICH Priorities

Draft-VICH Priorities Phase 4: This presentation is made based on the draft 4 – VICH Priorities Phase 4: (14 September 2015) 1. History 2. The Scope of VICH 3. Drivers behind the priorities for VICH phase 4 4. Priorities for the period VICH Steering Committee will soon publish the phase 4 VICH Priorities for next five years ( ) on the VICH website (

Draft-VICH Priorities Phase 4: Drivers behind the priorities for VICH phase 4 The drivers for VICH phase 4 include:

Draft-VICH Priorities Phase 4: Priorities for the period VICH will continue the following key activities. *Task Force of Anthelmintics GLs discussed including resistance to endo/ecto-parasiticides.

Draft-VICH Priorities Phase 4: Priorities for the period VICH will expand activities in the following areas.

13 3. Vision for the Future

Vision for the future (VICH Phase 4) Reaching out to the World

Desirable Future World for People & Animals 15 1.All people, domestic animals, wildlife are in good health. 2.No hunger is in the world. 3.Environment is healthy and ecosystem functions well.

Probable VICH contribution to Health 16 Easily access to enough VMPs with fair price in all of the world. Quick development of new VMPs. Examples of Areas -new infectious diseases -zoonosis -chronic diseases -alternative toxicity tests -improve QOL of animals -novel therapy Supply of VMPs with high quality, efficacy & safety.

Probable VICH contribution to Food Supply 17 Easily access to enough VMPs with fair price in all of the world. Quick development of new VMPs. Examples of Areas -healthy growth & efficient production -produce safe foods with high quality -reduce residues of VMPs in foods Supply of VMPs with high quality, efficacy & safety.

Probable VICH contribution to Environment 18 Easily access to enough VMPs with fair price in all of the world. Quick development of new VMPs. Examples of Areas -VMPs with no harmful effects for ecosystem -Easily degradable VMPs in the ecosystem -Collection and adequate treatment of used VMPs Supply of VMPs with high quality, efficacy & safety.

Vision for the Future 19 VICH Outreach have various possibilities, for example, -Regional dossiers and global dossiers with some regional differences -Harmonized/aligned pharmacovigilance systems -Global regulatory convergence VICH have a potential to contribute to the world sounder and happier through the outreach activity. VICH Outreach have various possibilities, for example, -Regional dossiers and global dossiers with some regional differences -Harmonized/aligned pharmacovigilance systems -Global regulatory convergence VICH have a potential to contribute to the world sounder and happier through the outreach activity.

Vision for the Future 20 VICH welcome collaboration with non-VICH countries, and VICH sincerely wish to improve the health for both human and animals by supplying the VICH standards and knowledge for the world.

21 Thank you for your Attention!